CORPORATE OVERVIEW

Therma Bright Inc. is a publicly traded company (TSVX:THRM) focused on servicing the $21 billion cosmeceutical industry. Therma Bright Inc. holds patents pending and the trademarks for Therozap™ and the trademark InterceptCS™ along with with regulatory approvals for its breakthrough thermal therapy technology. The Company’s technology uses heat and light energy to deliver effective, topical, pain free skin care.

Therma Bright Inc. has spent a significant investment in intellectual property and research and development for its InterceptCS™- cold sore device, the Therozap™ insect device, and will soon invest in a novel pain relief device. Therma’s current product lines address cold sore treatment and prevention, and the treatment of pain, itch and inflammation related to mosquito, bee, spider, mite, and jellyfish bites or stings. Therma Bright is in the research and development stage to develop a novel device for relief of pain associated with back, knee or other joint pain. Therma Bright is focused on building recurring revenue streams from its products and to incorporate intelligent technology such as AI or IoT.

The Company’s current focus is to market its products online through various social media networks, and to eventually re-establish relationships with major North American and Global retailers.

The Company is currently pursuing the redesign of Therma’s existing platforms to commercialize on new technologies.

MARKET

The skincare market is undergoing rapid growth fueled by an aging population, advances in skin care, and the convergence of pharmaceutical and cosmetics products – “cosmeceuticals”. Like cosmetics, cosmeceuticals are topically applied, but they contain ingredients that influence the biological function of the skin. Dermatological research suggests that the bioactive ingredients used in cosmeceuticals have benefits beyond the traditional cosmetics and thus provide protection, prevention and regeneration that surpass traditional cosmetics.

Today, as the demand increases for effective skin care treatments, consumers continue to educate themselves in the selection of home care products and alternatives to expensive procedures. Products that help people feel better and provide actual skin repair from the comfort of their home are expected to become the focus of the anti-aging skincare industry.

Therma occupies a unique market position. Its products tap into this new approach to skin care, combining clinically proven and scientifically endorsed technology with a cost-effective and efficient delivery method to treat a variety of skin conditions while providing a recurring revenue stream for the Company.

MARKET SUMMARY

According to various studies, the skin care device market is expected to reach USD 10.7 Billion by 2019.

Current medical research indicates that 20 to 40% of the population experience recurrent cold sore outbreaks. In the Canadian market alone, that figure translates from 5 million to as many as 10 million people who suffer recurrent bouts of cold sores. In the United States these estimates translate to between 40-80 million recurrent cold sore sufferers. The market potential for the Company’s InterceptCS™ product is substantial.

Therma Bright plans to test its Therozap™ technology at inhibiting the Zika virus and other mosquito borne diseases in the human body.

After consultation with various research laboratories specialized in studying mosquito borne disease, Therma Bright intends to test the TherOZap™ technology against the Zika and Dengue viruses.

According to the World Health Organization: “Dengue effects a much larger percentage of the world population with about half of the world’s population now at risk. Dengue is found in tropical and sub-tropical climates worldwide, mostly in urban and semi-urban areas. Severe dengue is a leading cause of serious illness and death among children in some Asian and Latin American countries.”

The Dengue, Zika and West Nile viruses are spread by the same mosquito which is known as the Aedes Aegypti mosquito. The Aedes Aegypti mosquito is known as a prolific daytime biter which often makes it harder for people to protect themselves after an infectious bite.

Therma Bright intends to test its TherOZap™ technology and hopes to prove the technology will be effective as a second line of defense after an individual has been bitten.

Therma Bright Inc. has gained a better understanding about the Zika virus through consultation with research groups and that the Zika and Dengue viruses may be susceptible to die-off with the use of the Company’s TherOZap™ technology. Once testing of the Company’s prototypes has been completed the Company intends to apply for regulatory approved claims and to market a consumer ready product to a large potential marketplace.